sabcs snippets: keynote-522 phase 3 results
Published 5 months ago • 379 plays • Length 11:45Download video MP4
Download video MP3
Similar videos
-
2:57
key data from the san antonio breast cancer symposium (sabcs) 2022
-
9:59
gs1-01: "phase 3 study of pembrolizumab chemotherapy vs placebo chemotherapy as neoadjuvant..."
-
5:38
sabcs snippets: five-year outcomes of the idea trial
-
0:56
the san antonio breast cancer symposium (sabcs) 2022
-
2:31
adjuvant/neoadjuvant therapy trials for breast cancer at sabcs 2021
-
4:17
keynote-522: efs sensitivity & subgroup analyses
-
1:28:08
2021 sabcs what changes monday morning? triple-negative breast cancer panel discussion
-
1:01:32
report from san antonio breast cancer symposium sabcs focusing on metastatic breast cancer
-
9:02
phase 3 keynote-522 results: pembro/chemo neoadjuvant, pembro adjuvant in early tnbc
-
0:49
san antonio breast cancer symposium 2022 highlights
-
5:46
sabcs snippets: immunology in hormone receptor positive breast cancer
-
4:23
sabcs snippets: shining a spotlight on lobular breast cancer
-
1:02:06
report back from san antonio breast cancer symposium (sabcs 2022)
-
4:22
sabcs snippets: destiny-breast06 phase iii trial
-
4:31
sabcs snippets: reflections on breast cancer advancements for 2023
-
4:20
keynote-522: 5-year follow-up of pembrolizumab in triple-negative breast cancer
-
4:54
keynote-522 updates: pembrolizumab plus neoadjuvant chemotherapy in early triple-negative breast...
-
5:37
catching up with peter schmid, md, lead investigator for keynote-522
-
3:07
highlights from sabcs 2021: t-dxd, keynote-355, pada-1 & emerald